The estimated Net Worth of Shelly Pinto is at least $337 Tisíc dollars as of 14 August 2024. Ms Pinto owns over 564 units of ALX Oncology stock worth over $199,577 and over the last 3 years she sold ALXO stock worth over $137,600.
Ms has made over 8 trades of the ALX Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 564 units of ALXO stock worth $1,455 on 14 August 2024.
The largest trade she's ever made was selling 7,345 units of ALX Oncology stock on 6 July 2023 worth over $47,889. On average, Ms trades about 1,172 units every 42 days since 2021. As of 14 August 2024 she still owns at least 91,549 units of ALX Oncology stock.
You can see the complete history of Ms Pinto stock trades at the bottom of the page.
Shelly Pinto is the VP of Fin. & Chief Accounting Officer at ALX Oncology.
Ms Pinto is 45, she's been the VP of Fin. & Chief Accounting Officer of ALX Oncology since . There are 7 older and no younger executives at ALX Oncology. The oldest executive at ALX Oncology Holdings Inc. is Dr. Corey S. Goodman Ph.D., 70, who is the Independent Exec. Chairman.
Shelly's mailing address filed with the SEC is C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at ALX Oncology have traded over $32,891,459 worth of ALX Oncology stock and bought 1,414,400 units worth $27,854,124 . The most active insiders traders include G. Walmsley Graham, Jack Nielsen a Capital Ix, Llc Vivo Capita.... On average, ALX Oncology executives and independent directors trade stock every 22 days with the average trade being worth of $89,694. The most recent stock trade was executed by Shelly Pinto on 14 August 2024, trading 564 units of ALXO stock currently worth $1,455.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
ALX Oncology executives and other stock owners filed with the SEC include: